Frontiers in pharmacology
Cure8 research brief
Why This Matters
Patients with psoriasis (and clinicians treating them) using IL‑17 pathway inhibitors may want to know whether certain fungal infections are being reported more often for newer agents; the paper highlights more frequent reporting of Candida events with bimekizumab in spontaneous databases, which may prompt clinical awareness.
Who Should Pay Attention
Clinicians prescribing IL‑17 inhibitors; pharmacovigilance researchers; dermatologists; drug-safety regulators.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper analyzed spontaneous adverse-event reports from two pharmacovigilance databases (FAERS and JADER) to compare how Candida-related events are reported for bimekizumab versus selective IL‑17A inhibitors in patients with psoriasis.
The authors found higher reporting odds ratios for any Candida-related event with bimekizumab versus the comparator group in both databases; oral and oesophageal candidiasis met pre-specified reporting thresholds in FAERS. The study focuses on reporting patterns (disproportionality), not clinical incidence or definitive comparative risk.
Spontaneous-report data can suggest signals but are affected by reporting biases, missing demographic details, and limited clinical verification. If you treat or counsel patients on IL‑17 pathway drugs, this paper supports being aware of Candida phenotypes (especially oral/oesophageal) and the need for targeted pharmacovigilance and clinical vigilance.
It does not provide guidance on managing or preventing infections.
Keep In Mind
Findings come from FAERS and JADER disproportionality analyses restricted to psoriasis reports and are limited by reporting biases, missing demographics, and lack of clinical verification. Results are reporting patterns, not incidence or proven comparative safety.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in pharmacology
AuthorsZhong H, Liu Y, Yu Y +1 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Safety of ozanimod and etrasimod in ulcerative colitis
People with ulcerative colitis considering or taking ozanimod or etrasimod may want to know about potential adverse events reported after these drugs entered the market, especially for nervous‑system, eye, and cardiac...
Extending the evidence on ustekinumab safety in Crohn’s disease: A pharmacovigilance disproportionality analysis of FAERS data
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases.
This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...